Welcome to our dedicated page for Shuttle Pharmaceuticals Holdings news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on Shuttle Pharmaceuticals Holdings stock.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) is a clinical stage pharmaceutical company pioneering innovative therapies aimed at curing cancers. Founded in 2012 by faculty members from Georgetown University Medical Center, Shuttle Pharma focuses on developing radiation sensitizers to enhance the efficacy of radiation therapy (RT). The company’s mission is to improve cancer treatment outcomes, prolong patient survival, and elevate the quality of life for those undergoing therapy.
Shuttle Pharma's flagship product, Ropidoxuridine (IPdR), is a leading candidate designed to be used in combination with RT for treating glioblastoma, a lethal brain tumor currently without a cure. The company has received positive feedback from the U.S. Food and Drug Administration (FDA), including a 'Safe to Proceed' letter, enabling the commencement of Phase II clinical trials. The FDA's guidance has paved the way for Shuttle Pharma to develop Ropidoxuridine further as a radiation sensitizer.
In addition to Ropidoxuridine, Shuttle Pharma is advancing its predictive biomarker program for prostate cancer. This initiative includes licensing intellectual property from Georgetown University to develop diagnostic blood tests. These tests aim to predict the success or failure of RT in prostate cancer patients, thereby informing treatment decisions and improving patient management.
Shuttle Pharma operates with a strong collaborative ethos, partnering with academic institutions and leveraging grant funding from entities like the National Institutes of Health (NIH). The company’s research also extends to histone deacetylase (HDAC) inhibitors, such as its lead HDAC6 inhibitor candidate, SP-2-225, which aims to prevent tumor relapse and enhance antitumor immune responses.
Financially, Shuttle Pharma is actively involved in capital raising initiatives to support its ambitious research and development goals. A recent Rights Offering aims to raise up to $4.5 million, supplementing the company’s resources to advance its clinical trials and diagnostic programs.
Overall, Shuttle Pharmaceuticals Holdings, Inc. is at the forefront of developing groundbreaking therapies that could revolutionize cancer treatment by making radiation therapy more effective and less toxic.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced that it will lease new laboratory and office space in Gaithersburg, Maryland, starting in June 2023. This expansion aims to support the development of its lead drug candidate, Ropidoxuridine, which is designed to sensitize cancer cells during radiation therapy. The company is advancing a Phase II clinical trial for brain cancer patients and plans to submit an Investigational New Drug application to the FDA by Q2 2023. Shuttle's platform seeks to address clinical needs for radiation sensitizers and has received NIH funding for related research.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH), a pharmaceutical company dedicated to enhancing cancer treatment outcomes, announced that CEO Anatoly Dritschilo will present at the Lytham Partners Investor Select Conference on January 31, 2023. This virtual event will include one-on-one meetings with investors, providing a platform for discussion on the company's mission to improve radiation therapy efficacy while minimizing side effects. A webcast of the presentation will be available at 9:00 AM ET on the same day, with a replay option afterward. For more details, visit their website.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced that its Chairman and CEO, Anatoly Dritschilo, will ring the Nasdaq opening bell on January 18, 2023. This event marks the company's recent IPO and highlights its commitment to developing therapies aimed at improving cancer treatment outcomes through radiation therapy. Dritschilo expressed excitement about their lead product candidate and the company's mission to enhance the effectiveness of radiation therapy while reducing side effects, aiming to benefit thousands of patients currently lacking effective treatment options.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) announced a private placement of a $4.3 million senior secured convertible note and warrant. The company will receive $4.0 million initially, with a potential for an additional $2.4 million if warrants are exercised at $2.35 per share. Monthly amortizations can be settled in cash or stock and the deal has a 5% annual interest rate.
This initiative aims to support Shuttle's mission to enhance cancer treatment outcomes while minimizing radiation side effects.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) announced the publication of a manuscript that discusses immune responses in cancer patients post-radiation therapy. The study, authored by Dr. Amrita K Cheema, reveals how radiation therapy induces innate immune responses in patients with prostate cancer. Key findings include an increase in DNA Damage Response (DDR) shortly after treatment, and sustained immune signaling for up to three months. The research may inform the development of biomarkers and therapeutic strategies for better cancer treatment outcomes. The publication is available in Clinical Cancer Research.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has published research detailing novel prostate cancer cell lines derived from African American men aimed at enhancing precision medicine. This work, part of a NIH-funded 'Moonshot' project, addresses significant health disparities in prostate cancer within this demographic. The research is expected to facilitate studies on cancer biology and drug effectiveness. The initiative underscores the company's commitment to improving cancer treatment outcomes for African American patients.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) provided a corporate update following its quarterly report for Q3 2022. Highlights include an IPO raising $10 million, along with an additional $1.5 million from an overallotment option. The company announced an agreement with TCG GreenChem to manufacture its lead drug candidate, Ropidoxuridine, aimed at enhancing cancer treatment outcomes through radiation therapy. Shuttle Pharma also engaged Theradex Oncology for clinical study preparations and received patents in the U.S. and Hong Kong for its HDAC inhibitor technology.
Shuttle Pharmaceuticals Holdings (SHPH) announced its collaboration with Theradex Oncology to prepare for a Phase II clinical study of Ropidoxuridine, an innovative cancer treatment aimed at enhancing the efficacy of radiation therapy (RT). The IND application is expected to be submitted to the FDA by Q2 2023. Ropidoxuridine, designed to improve patient outcomes in glioblastoma treatment, has received orphan-drug designation from the FDA. The market for radiation sensitizers is projected to exceed $4 billion, with expected growth in patient numbers and treatment effectiveness.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced the appointment of Dr. Bette Jacobs to its Board of Directors on November 1, 2022. Dr. Jacobs will serve on the Audit and Nominating Committees, bringing extensive experience in healthcare system design, equity, and diversity. She is a professor at Georgetown University and has held various leadership positions, including dean and vice president at Honda of America Manufacturing. Dr. Jacobs expressed her commitment to enhancing the company's mission of improving cancer treatment outcomes.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a partnership with TCG GreenChem, Inc. to manufacture Ropidoxuridine, its lead clinical sensitizer drug candidate. This agreement aims to facilitate the formulation of Ropidoxuridine for clinical trials targeting brain tumors, sarcomas, and pancreatic cancers. The FDA has granted orphan-drug designation for Ropidoxuridine in glioblastoma treatment. The agreement also includes process research and optimization to enhance drug development. The market for radiation sensitizers is projected to exceed $4.0 billion due to a growing patient base.
FAQ
What is the current stock price of Shuttle Pharmaceuticals Holdings (SHPH)?
What is the market cap of Shuttle Pharmaceuticals Holdings (SHPH)?
What does Shuttle Pharmaceuticals Holdings, Inc. specialize in?
What is Ropidoxuridine?
What is the significance of the FDA's 'Safe to Proceed' letter for Shuttle Pharmaceuticals?
How is Shuttle Pharmaceuticals advancing prostate cancer treatment?
What types of cancer therapies is Shuttle Pharma developing?
What collaboration does Shuttle Pharma have with Georgetown University?
What are the financial strategies of Shuttle Pharmaceuticals?
What is the company's mission?
What other cancers besides glioblastoma is Shuttle Pharma targeting?
How does Shuttle Pharma contribute to the field of cancer research?
